NCI invites revision applications from NIH-funded investigators with active R01 awards or NCI-funded investigators with active U01, P01, or P50 awards to address one of the 12 PQs. 

Four of the 12 PQs may be of particular interest to population science researchers:

• PQ-2: What molecular mechanisms influence disease penetrance in individuals who inherit a cancer susceptibility gene?

• PQ-3: How do variations in tumor-associated immune responses contribute to differences in cancer risk, incidence, or progression?

• PQ-9: What are the molecular and/or cellular mechanisms that underlie the development of cancer therapy-induced severe adverse sequelae?

• PQ-12: What methods and approaches induce physicians and health systems to abandon ineffective interventions or discourage adoption of unproven interventions?

The other eight PQs can be viewed on the PQ Initiative's website.

To be considered eligible to respond to one of the PQ FOAs, investigators must have at least two years remaining in their original award period or no-cost extension. No more than two years of support can be requested and the budget cap is $150,000 direct costs per year.

The application receipt dates are June 28 and October 28, 2016. The revision applications will be reviewed by the same Special Emphasis Panels (SEPs) that review the Provocative Questions initiative R01 and R21 applications.

Learn more about the PQ FOAs through the NIH Guide for Grants and Contracts:

• RFA-CA-16-010 (R01)
• RFA-CA-16-011 (U01)
• RFA-CA-16-012 (P50)
• RFA-CA-16-013 (P01)

For questions or more information about the PQ Initiative, visit the Initiative's website or e-mail NCIProvocativeQuestions@mail.nih.gov.

The 107th Annual Meeting of the American Association for Cancer Research (AACR) will take place from April 16-20, 2016 in New Orleans, Louisiana. To help attendees get the most out of this year's presentations, the Epidemiology and Genomics Research Program (EGRP) has assembled a list of selected sessions presented by NCI staff and grantees that highlight important resources and topics in cancer epidemiology and genomics, funding opportunities, and grantsmanship issues. We are especially proud to acknowledge those EGRP scientific staff and NCI- and EGRP-supported extramural researchers among the presenters (in italics below).

• 10:30 a.m. - 12:30 p.m., Fellowships, Career Development Awards, and Transitioning to Independence Awards (Room 352)
• 1:00 p.m. - 3:00 p.m., NCI Center for Strategic Scientific Initiatives (CSSI) Programs and Related NCI Opportunities, Tools, and Resources (Room 352)
• This session will include EGRP's Amy Kennedy, Ph.D., M.P.H. and other NCI staff.
• 3:00 p.m. - 5:00 p.m., Minisymposium, Biomarkers and Other Epidemiologic Factors in Cancer Prognosis (Room 357)
• This minisymposium is chaired by EGRP grantees James R. Cerhan, M.D., Ph.D. of the Mayo Clinic College of Medicine and Xiao-Ou Shu, M.D., Ph.D. of the Vanderbilt University School of Medicine.
• 4:15 p.m. - 5:45 p.m., Infrastructure and Resources to Support Cancer Biomarker Discovery Using Metabolite Profiling (Room 352)
• This session is moderated by EGRP's Krista A. Zanetti, Ph.D., M.P.H., R.D. and includes Barbara Spalholz, Ph.D. of NCI's Division of Cancer Biology; EGRP grantee Oliver Fiehn, Ph.D., M.S. of the University of California, Davis; and others.

• 7:00 a.m. - 8:00 a.m., Meet-the-Expert Session, From Epidemiology to Clinical and Public Health Impact: A Case-Study of Liver Cancer in the United States (Room 288)
• This session includes EGRP's Tram K. Lam, Ph.D., M.P.H.
• 10:30 a.m. - 12:15 p.m., Funding Opportunities for Cancer Research at Multiple NIH Institutes and Centers with NIH Experts (Room 352)
• 12:30 p.m. - 2:15 p.m., Technology Transfer and Intellectual Property: Financial and Career Opportunities for Researchers (Room 352)
• 1:00 p.m. - 2:45 p.m., Insights on Genetic Risk and Biologic Mechanisms of Cancer from Genome-Wide Studies of over 500,000 Cases and Controls: Results from the OncoArray Network (Room 391)
• This session, featuring the EGRP-supported OncoArray Network, includes EGRP grantees Christopher I. Amos, Ph.D., of the Dartmouth Geisel School of Medicine; Sara Lindstrom, Ph.D., M.Sc., of the University of Washington School of Public Health; and John S. Witte, Ph.D., of the University of California, San Francisco.
• 2:30 p.m. - 4:00 p.m., NCI SBIR Programs Support Technology Innovation for Cancer Detection and Treatment - with Dekk-Tec, Inc. and RefleXion Medical (Room 352)
• 3:00 p.m. - 5:00 p.m., Room 275, Minisymposium, Endogenous and Exogenous Factors in Cancer Epidemiology throughout the Life Course
• This minisymposium is chaired by EGRP grantees Jo L. Freudenheim, Ph.D., of the University at Buffalo and Marc T. Goodman, Ph.D., of Cedars-Sinai Medical Center.
• 4:15 p.m. - 5:45 p.m., Informatics Technology for Cancer Research (Room 352)